Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX
Background Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors. Patients and methods In this two-step phase I trial, seventeen and eleven patients were e...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2012-03, Vol.69 (3), p.807-814 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 814 |
|---|---|
| container_issue | 3 |
| container_start_page | 807 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 69 |
| creator | Mazard, T. Ychou, M. Thezenas, S. Poujol, S. Pinguet, F. Thirion, A. Bleuse, J. P. Portales, F. Samalin, E. Assenat, E. |
| description | Background
Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors.
Patients and methods
In this two-step phase I trial, seventeen and eleven patients were enrolled in the XELIRI and XELIRINOX stages, respectively.
Results
In XELIRI, a total of 136 chemotherapy cycles were administered with a median number of 8 cycles per patient (2–16). Main dose-limiting toxicities (DLT) were grade 3–4 neutropenia, with one toxicity-related death. Maximum tolerated dose (MTD) for capecitabine combined with 180 mg/m
2
of irinotecan was 3,500 mg/m
2
/day. In XELIRINOX, capecitabine starting dose was 2,500 mg/m
2
/day. Fifty-eight chemotherapy cycles were administered with a median of 4 cycles per patient (1–16). DLT included 3 grade 4 neutropenia, associated with 1 grade 3 diarrhea, and 1 grade 4 pneumopathy leading to patient death. MTD for capecitabine with 180 mg/m
2
of irinotecan and 85 mg/m
2
of oxaliplatin was 3,000 mg/m
2
/day. The recommended doses for capecitabine were 3,000 and 2,500 mg/m
2
/day D1–D7 in combination with 180 mg/m
2
of irinotecan in XELIRI, plus 85 mg/m
2
of oxaliplatin in XELIRINOX (D1 = D14), respectively.
Conclusion
XELIRI and XELIRINOX regimens are feasible and warrant further investigation in combination with targeted therapy in metastatic colorectal cancer patients. |
| doi_str_mv | 10.1007/s00280-011-1764-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_923433040</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2594972581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-77a0e9cd48952243a45d98d2021b3f7daedea47b4da184b69c6da1e1e3ce7443</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS0EokPhAdggC4ldA9c_mSTdoaqFkUZUQl10F904N4xLEgfb0TB9PV4Mlwx0hWTJR_Z37rnSYey1gPcCoPgQAGQJGQiRiWKts_snbCW0khmUWj1lK1BaZ3kB-oS9COEOALRQ6jk7kRJUUUm5Yr-uCINtbG_jgbuON3ZP9L0_cOOGxo4YrRu52dHg4o48Tge-t3HHDU5kbMSE0Bm33o4uksHxjOPYcvcTezv1yTzydKYkaIxhsQ4UMcT0ZHhwvW15nAfnwzn3FOY-UWkL5HHvshBp4tMOA_ENj95if85vL7ebr5s_KYv8cn37kj3rsA_06nifspury5uLz9n2-tPm4uM2MxogZkWBQJVpdVnlUmqFOm-rspUgRaO6okVqCXXR6BZFqZt1ZdZJkSBlqNBanbK3y9jJux8zhVjfudmPKbGupNJKgYYEiQUy3oXgqasnbwf0h1pA_VBavZRWp9Lqh9Lq--R5cxw8NwO1_xx_W0rAuyOAwWDfeRyNDY9cnle6KsvEyYUL6Wv8Rv5xw_-n_wZfkLMF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>923433040</pqid></control><display><type>article</type><title>Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Mazard, T. ; Ychou, M. ; Thezenas, S. ; Poujol, S. ; Pinguet, F. ; Thirion, A. ; Bleuse, J. P. ; Portales, F. ; Samalin, E. ; Assenat, E.</creator><creatorcontrib>Mazard, T. ; Ychou, M. ; Thezenas, S. ; Poujol, S. ; Pinguet, F. ; Thirion, A. ; Bleuse, J. P. ; Portales, F. ; Samalin, E. ; Assenat, E.</creatorcontrib><description>Background
Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors.
Patients and methods
In this two-step phase I trial, seventeen and eleven patients were enrolled in the XELIRI and XELIRINOX stages, respectively.
Results
In XELIRI, a total of 136 chemotherapy cycles were administered with a median number of 8 cycles per patient (2–16). Main dose-limiting toxicities (DLT) were grade 3–4 neutropenia, with one toxicity-related death. Maximum tolerated dose (MTD) for capecitabine combined with 180 mg/m
2
of irinotecan was 3,500 mg/m
2
/day. In XELIRINOX, capecitabine starting dose was 2,500 mg/m
2
/day. Fifty-eight chemotherapy cycles were administered with a median of 4 cycles per patient (1–16). DLT included 3 grade 4 neutropenia, associated with 1 grade 3 diarrhea, and 1 grade 4 pneumopathy leading to patient death. MTD for capecitabine with 180 mg/m
2
of irinotecan and 85 mg/m
2
of oxaliplatin was 3,000 mg/m
2
/day. The recommended doses for capecitabine were 3,000 and 2,500 mg/m
2
/day D1–D7 in combination with 180 mg/m
2
of irinotecan in XELIRI, plus 85 mg/m
2
of oxaliplatin in XELIRINOX (D1 = D14), respectively.
Conclusion
XELIRI and XELIRINOX regimens are feasible and warrant further investigation in combination with targeted therapy in metastatic colorectal cancer patients.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-011-1764-z</identifier><identifier>PMID: 22037922</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject><![CDATA[Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Camptothecin - administration & dosage ; Camptothecin - adverse effects ; Camptothecin - analogs & derivatives ; Camptothecin - pharmacokinetics ; Camptothecin - therapeutic use ; Cancer Research ; Capecitabine ; Chromatography, High Pressure Liquid ; Deoxycytidine - administration & dosage ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - pharmacokinetics ; Deoxycytidine - therapeutic use ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Feasibility Studies ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Fluorouracil - analogs & derivatives ; Fluorouracil - pharmacokinetics ; Fluorouracil - therapeutic use ; Gastroenterology. Liver. Pancreas. Abdomen ; Glucuronosyltransferase - genetics ; Humans ; Male ; Maximum Tolerated Dose ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Mutation ; Neoplasm Metastasis ; Neoplasms - drug therapy ; Neoplasms - genetics ; Neoplasms - pathology ; Oncology ; Organoplatinum Compounds - administration & dosage ; Organoplatinum Compounds - adverse effects ; Organoplatinum Compounds - pharmacokinetics ; Organoplatinum Compounds - therapeutic use ; Original Article ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Prospective Studies ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors]]></subject><ispartof>Cancer chemotherapy and pharmacology, 2012-03, Vol.69 (3), p.807-814</ispartof><rights>Springer-Verlag 2011</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-77a0e9cd48952243a45d98d2021b3f7daedea47b4da184b69c6da1e1e3ce7443</citedby><cites>FETCH-LOGICAL-c400t-77a0e9cd48952243a45d98d2021b3f7daedea47b4da184b69c6da1e1e3ce7443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-011-1764-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-011-1764-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25594988$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22037922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mazard, T.</creatorcontrib><creatorcontrib>Ychou, M.</creatorcontrib><creatorcontrib>Thezenas, S.</creatorcontrib><creatorcontrib>Poujol, S.</creatorcontrib><creatorcontrib>Pinguet, F.</creatorcontrib><creatorcontrib>Thirion, A.</creatorcontrib><creatorcontrib>Bleuse, J. P.</creatorcontrib><creatorcontrib>Portales, F.</creatorcontrib><creatorcontrib>Samalin, E.</creatorcontrib><creatorcontrib>Assenat, E.</creatorcontrib><title>Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Background
Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors.
Patients and methods
In this two-step phase I trial, seventeen and eleven patients were enrolled in the XELIRI and XELIRINOX stages, respectively.
Results
In XELIRI, a total of 136 chemotherapy cycles were administered with a median number of 8 cycles per patient (2–16). Main dose-limiting toxicities (DLT) were grade 3–4 neutropenia, with one toxicity-related death. Maximum tolerated dose (MTD) for capecitabine combined with 180 mg/m
2
of irinotecan was 3,500 mg/m
2
/day. In XELIRINOX, capecitabine starting dose was 2,500 mg/m
2
/day. Fifty-eight chemotherapy cycles were administered with a median of 4 cycles per patient (1–16). DLT included 3 grade 4 neutropenia, associated with 1 grade 3 diarrhea, and 1 grade 4 pneumopathy leading to patient death. MTD for capecitabine with 180 mg/m
2
of irinotecan and 85 mg/m
2
of oxaliplatin was 3,000 mg/m
2
/day. The recommended doses for capecitabine were 3,000 and 2,500 mg/m
2
/day D1–D7 in combination with 180 mg/m
2
of irinotecan in XELIRI, plus 85 mg/m
2
of oxaliplatin in XELIRINOX (D1 = D14), respectively.
Conclusion
XELIRI and XELIRINOX regimens are feasible and warrant further investigation in combination with targeted therapy in metastatic colorectal cancer patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Camptothecin - administration & dosage</subject><subject>Camptothecin - adverse effects</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - pharmacokinetics</subject><subject>Camptothecin - therapeutic use</subject><subject>Cancer Research</subject><subject>Capecitabine</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - pharmacokinetics</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Fluorouracil - pharmacokinetics</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Glucuronosyltransferase - genetics</subject><subject>Humans</subject><subject>Male</subject><subject>Maximum Tolerated Dose</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Mutation</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - pathology</subject><subject>Oncology</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Organoplatinum Compounds - pharmacokinetics</subject><subject>Organoplatinum Compounds - therapeutic use</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Prospective Studies</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc1u1DAUhS0EokPhAdggC4ldA9c_mSTdoaqFkUZUQl10F904N4xLEgfb0TB9PV4Mlwx0hWTJR_Z37rnSYey1gPcCoPgQAGQJGQiRiWKts_snbCW0khmUWj1lK1BaZ3kB-oS9COEOALRQ6jk7kRJUUUm5Yr-uCINtbG_jgbuON3ZP9L0_cOOGxo4YrRu52dHg4o48Tge-t3HHDU5kbMSE0Bm33o4uksHxjOPYcvcTezv1yTzydKYkaIxhsQ4UMcT0ZHhwvW15nAfnwzn3FOY-UWkL5HHvshBp4tMOA_ENj95if85vL7ebr5s_KYv8cn37kj3rsA_06nifspury5uLz9n2-tPm4uM2MxogZkWBQJVpdVnlUmqFOm-rspUgRaO6okVqCXXR6BZFqZt1ZdZJkSBlqNBanbK3y9jJux8zhVjfudmPKbGupNJKgYYEiQUy3oXgqasnbwf0h1pA_VBavZRWp9Lqh9Lq--R5cxw8NwO1_xx_W0rAuyOAwWDfeRyNDY9cnle6KsvEyYUL6Wv8Rv5xw_-n_wZfkLMF</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>Mazard, T.</creator><creator>Ychou, M.</creator><creator>Thezenas, S.</creator><creator>Poujol, S.</creator><creator>Pinguet, F.</creator><creator>Thirion, A.</creator><creator>Bleuse, J. P.</creator><creator>Portales, F.</creator><creator>Samalin, E.</creator><creator>Assenat, E.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20120301</creationdate><title>Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX</title><author>Mazard, T. ; Ychou, M. ; Thezenas, S. ; Poujol, S. ; Pinguet, F. ; Thirion, A. ; Bleuse, J. P. ; Portales, F. ; Samalin, E. ; Assenat, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-77a0e9cd48952243a45d98d2021b3f7daedea47b4da184b69c6da1e1e3ce7443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Camptothecin - administration & dosage</topic><topic>Camptothecin - adverse effects</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - pharmacokinetics</topic><topic>Camptothecin - therapeutic use</topic><topic>Cancer Research</topic><topic>Capecitabine</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - pharmacokinetics</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Fluorouracil - pharmacokinetics</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Glucuronosyltransferase - genetics</topic><topic>Humans</topic><topic>Male</topic><topic>Maximum Tolerated Dose</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Mutation</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - pathology</topic><topic>Oncology</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Organoplatinum Compounds - pharmacokinetics</topic><topic>Organoplatinum Compounds - therapeutic use</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Prospective Studies</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mazard, T.</creatorcontrib><creatorcontrib>Ychou, M.</creatorcontrib><creatorcontrib>Thezenas, S.</creatorcontrib><creatorcontrib>Poujol, S.</creatorcontrib><creatorcontrib>Pinguet, F.</creatorcontrib><creatorcontrib>Thirion, A.</creatorcontrib><creatorcontrib>Bleuse, J. P.</creatorcontrib><creatorcontrib>Portales, F.</creatorcontrib><creatorcontrib>Samalin, E.</creatorcontrib><creatorcontrib>Assenat, E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mazard, T.</au><au>Ychou, M.</au><au>Thezenas, S.</au><au>Poujol, S.</au><au>Pinguet, F.</au><au>Thirion, A.</au><au>Bleuse, J. P.</au><au>Portales, F.</au><au>Samalin, E.</au><au>Assenat, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2012-03-01</date><risdate>2012</risdate><volume>69</volume><issue>3</issue><spage>807</spage><epage>814</epage><pages>807-814</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Background
Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors.
Patients and methods
In this two-step phase I trial, seventeen and eleven patients were enrolled in the XELIRI and XELIRINOX stages, respectively.
Results
In XELIRI, a total of 136 chemotherapy cycles were administered with a median number of 8 cycles per patient (2–16). Main dose-limiting toxicities (DLT) were grade 3–4 neutropenia, with one toxicity-related death. Maximum tolerated dose (MTD) for capecitabine combined with 180 mg/m
2
of irinotecan was 3,500 mg/m
2
/day. In XELIRINOX, capecitabine starting dose was 2,500 mg/m
2
/day. Fifty-eight chemotherapy cycles were administered with a median of 4 cycles per patient (1–16). DLT included 3 grade 4 neutropenia, associated with 1 grade 3 diarrhea, and 1 grade 4 pneumopathy leading to patient death. MTD for capecitabine with 180 mg/m
2
of irinotecan and 85 mg/m
2
of oxaliplatin was 3,000 mg/m
2
/day. The recommended doses for capecitabine were 3,000 and 2,500 mg/m
2
/day D1–D7 in combination with 180 mg/m
2
of irinotecan in XELIRI, plus 85 mg/m
2
of oxaliplatin in XELIRINOX (D1 = D14), respectively.
Conclusion
XELIRI and XELIRINOX regimens are feasible and warrant further investigation in combination with targeted therapy in metastatic colorectal cancer patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>22037922</pmid><doi>10.1007/s00280-011-1764-z</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2012-03, Vol.69 (3), p.807-814 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_923433040 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Camptothecin - pharmacokinetics Camptothecin - therapeutic use Cancer Research Capecitabine Chromatography, High Pressure Liquid Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacokinetics Deoxycytidine - therapeutic use Dose-Response Relationship, Drug Drug Administration Schedule Feasibility Studies Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Fluorouracil - analogs & derivatives Fluorouracil - pharmacokinetics Fluorouracil - therapeutic use Gastroenterology. Liver. Pancreas. Abdomen Glucuronosyltransferase - genetics Humans Male Maximum Tolerated Dose Medical sciences Medicine Medicine & Public Health Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation Neoplasm Metastasis Neoplasms - drug therapy Neoplasms - genetics Neoplasms - pathology Oncology Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Organoplatinum Compounds - pharmacokinetics Organoplatinum Compounds - therapeutic use Original Article Pharmacology. Drug treatments Pharmacology/Toxicology Prospective Studies Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors |
| title | Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T12%3A04%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20of%20biweekly%20combination%20chemotherapy%20with%20capecitabine,%20irinotecan,%20and%20oxaliplatin%20in%20patients%20with%20metastatic%20solid%20tumors:%20results%20of%20a%20two-step%20phase%20I%20trial:%20XELIRI%20and%20XELIRINOX&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Mazard,%20T.&rft.date=2012-03-01&rft.volume=69&rft.issue=3&rft.spage=807&rft.epage=814&rft.pages=807-814&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-011-1764-z&rft_dat=%3Cproquest_cross%3E2594972581%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=923433040&rft_id=info:pmid/22037922&rfr_iscdi=true |